4.6 Article

Quality of Life in Patients with Leber Hereditary Optic Neuropathy

期刊

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
卷 50, 期 7, 页码 3112-3115

出版社

ASSOC RESEARCH VISION OPHTHALMOLOGY INC
DOI: 10.1167/iovs.08-3166

关键词

-

资金

  1. United Mitochondrial Diseases Foundation
  2. European Union Research Framework Programme
  3. MRC Research Fellow
  4. Wellcome Trust Senior Fellow in Clinical Science

向作者/读者索取更多资源

PURPOSE. Leber hereditary optic neuropathy (LHON) is an inherited mitochondrial optic neuropathy characterized by bilateral, severe loss of central vision. In this study, the first formal assessment was conducted of visual disability in affected and unaffected individuals from molecularly confirmed LHON pedigrees. METHODS. Four hundred two LHON carriers-196 affected and 206 unaffected-from 125 genealogically distinct pedigrees were prospectively interviewed using the well-validated visual function index (VF-14) questionnaire: m.3460G>A (n = 71), m.11778G>A (n = 270), and m.14484T>C (n = 61). RESULTS. The mean age of onset of visual loss was 27.9 years (SD, 14.9) and mean disease duration was 15.5 years (SD, 15.4), with 74.5% of the affected subjects being men. The mean VF-14 score was 25.1 (SD, 20.8) in the affected patients, compared with 97.3 (SD, 7.1) in the unaffected carriers. Within the affected group, VF-14 score did not worsen with increasing disease duration and individuals with the m.14484T>C mutation had higher VF-14 scores compared with those in the m.3460G>A and m. 11778G>A groups. Reading small print and reading a newspaper or book were the two VF-14 items that presented the greatest difficulty. CONCLUSIONS. LHON has a severe negative impact on quality of life and has the worst VF-14 score when compared with other previously studied ophthalmic disorders. However, affected LHON carriers can be reassured that their level of visual impairment is unlikely to progress with time. The VF-14 questionnaire will be a useful tool for assessing the natural history of LHON and measuring outcome in future treatment trials. (Invest Ophthalmol Vis Sci. 2009; 50:3112-3115) DOI:10.1167/iovs.08-3166

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据